Skip to main content
Nuclear medicine

Nuclear medicine

FDG-PET/CT provides valuable oesophageal cancer updates

05 Sep 2018

FDG-PET/CT could be very helpful in calculating the risk of developing interval metastasis during neoadjuvant chemoradiotherapy for oesophageal cancer, and it could lead to other more appropriate restaging modalities for patients, according to a study published in the September issue of the European Journal of Nuclear Medicine and Molecular Imaging.

In an analysis of more than 700 consecutive patients, Dutch and US researchers discovered that 8% of subjects developed metastases during treatment and thus avoided a potentially unnecessary oesophagectomy because of this routine FDG-PET/CT restaging protocol.

“Accurate preoperative detection of interval metastasis of [oesophageal] cancer is crucial for optimal selection of patients suitable for surgery,” wrote the researchers, led by Lucas Goense, from University Medical Center Utrecht in the Netherlands. “In patients with accurately detected interval metastasis, surgery is expected to provide no benefit in terms of survival, but rather to decrease quality of life due to highly morbid surgery with subsequent recovery time.”

PET/CT restaging

Treatment debate

It is estimated that more than 450,000 people contract oesophageal cancer on an annual basis. In cases of non-metastasized oesophageal cancer, neoadjuvant chemoradiotherapy is the standard of care, while patients with inoperable locally advanced forms of the disease face definitive chemoradiotherapy.

“Currently, there is disagreement between guidelines as to whether all patients should be restaged after chemoradiotherapy,” the authors wrote. “At present, little is known about which patients are at risk of developing interval metastases.”

Thus the objective of this study was to assess FDG-PET/CT’s ability to detect and to diagnose interval metastasis and identify predictors of interval metastases in a large cohort of patients with oesophageal cancer.

Researchers from University Medical Center Utrecht and University of Texas MD Anderson Cancer Center in Houston, Texas, looked at a total of 783 consecutive patients (mean age, 62.5 years, ±10.6 years) between 2006 and 2015 who were diagnosed with oesophageal cancer. The most predominant tumour type was adenocarcinoma (86%), while the majority of patients (87%) were in clinical tumour stage III (Eur. J. Nucl. Med. Mol. Imaging 45 1742).

The subjects underwent an FDG-PET/CT scan (Discovery RX, ST, or STE; GE Healthcare) before and after completion of chemoradiotherapy. After fasting for six hours, patients received between 555 and 740 MBq of FDG.

The mean time between completion of chemoradiotherapy and FDG-PET/CT restaging was 41.3 days (± 10.7 days). After completion of chemoradiotherapy, 450 patients (57%) underwent oesophageal resection.

In reviewing the FDG-PET/CT results, Goense and colleagues observed 109 patients (14%) presented with new potential metastatic lesions during restaging. Of these patients, 65 cases were true-positive results (8.3%) confirmed through clinical follow-up (44 patients, 68%) or by histology (21 patients, 32%). By comparison, there were 44 false-positive (5.3%) results.

As the reference standard, the researchers used histological verification or clinical follow-up for diagnostic accuracy measures based on a per-patient basis, and calculated the sensitivity, specificity and other metrics for PET/CT.

Metastasis detection

In addition, patients with no evidence of interval metastasis after initial restaging with FDG-PET/CT were still at risk of developing new metastatic lesions. The researchers discovered 22 such lesions (50%) among the 44 false-negative results within three months of follow-up.

Because there were no new lesions detected in 86% of patients during restaging after chemoradiotherapy, the authors indicated a “limited impact on patient management is anticipated in the majority of patients … Consequently, a more individualized application of FDG-PET/CT restaging could reduce the number of unbeneficial diagnostic tests.”

On a more sombre note, patients with interval metastases had a significantly shorter median overall survival of only six months (range, four to eight months), compared with patients without metastatic disease at restaging who had a mean survival time of with 59 months (47 to 70 months) (p = 0.001).

Predictive score

Goense and colleagues also noted the following independent risk factors for the development of interval metastases:

  • Clinical nodal involvement
  • Endoscopic ultrasound-based tumour length of 4 cm or more
  • Squamous cell tumour histology
  • Baseline maximum standard uptake values of 9.6 or greater

“Based on these findings, a prediction score was developed that may provide physicians a tool for objectively assessing the risk of interval metastasis in patients with [oesophageal] cancer,” the authors wrote. Based on the criteria, a prediction score with an “optimism adjusted C-index of 0.67 demonstrated accurate calibration.”

Patients with low predictive scores “have limited risk of interval metastases”, the authors wrote, and restaging of these patients based on FDG-PET/CT “may be safely omitted without subjecting the patient to the risks of further diagnostic tests”.

The prediction score also “may especially be of interest for hospitals/regions with limited resources that have not yet implemented FDG-PET/CT restaging in their routine clinical practice due to associated costs,” the authors advocated.

Because this study was conducted in one facility, Goense and colleagues cautioned that the results may not be applicable to other institutions. “Therefore, external validation of the developed risk prediction score is recommended to determine generalizability,” they concluded.

  • This article was originally published on © 2018 by Any copying, republication or redistribution of content is expressly prohibited without the prior written consent of
Copyright © 2024 by IOP Publishing Ltd and individual contributors